Guests Jacob Plieth, Madeleine Armstrong and Nuvalent CEO, Jim Porter join Daphne Zohar and Josh Schimmer on this week’s Biotech Hangout to discuss the big deal of the week: Merck and Daichii’s co-development & co-commercialization deal for three ADCs (worth up to $16.5B), plus Nuvalent’s $300M raise and recent data. They also discuss the recent ESMO data breach, PTC Therapeutics’ agreement with Royalty Pharma and Monte Rosa’s partnership with Roche. Other topics include Revolution Medicines’ KRAS data, the FDA’s decision to clear Nkarta’s IND application, Pfizer’s revenue guidance related to Covid products and overall CEO and industry sentiment. *This episode aired on October 20, 2023
Fler avsnitt av Biotech Hangout
Visa alla avsnitt av Biotech HangoutBiotech Hangout med Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
